← Back to patent-cliff list
68Ga-NODAGA-E[c(RGDyK)]2
Tier C — Watch / trade68Ga-NODAGA-E[c(RGDyK)]2
Rigshospitalet
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：Not applicable
Indications (approved)：Neuroendocrine tumour, Ischaemic heart disease, Myocardial infarction
Regional status
US
-
EU
Phase II
2017-12-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 68Ga-NODAGA-E[c(RGDyK)]2?
Approved indications include: Neuroendocrine tumour, Ischaemic heart disease, Myocardial infarction.
When does the 68Ga-NODAGA-E[c(RGDyK)]2 patent expire?
No public expiry year is available for 68Ga-NODAGA-E[c(RGDyK)]2 yet; this page updates once verified.
How do I get a quote for 68Ga-NODAGA-E[c(RGDyK)]2 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09